Rathin Gosavi1,2, Clemente Chia3,4, Michael Michael5, Alexander G Heriot3,6,7, Satish K Warrier3,6,7, Joseph C Kong3,6,7. 1. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. gosavirr@gmail.com. 2. Colorectal Surgery Department, Alfred Health, Melbourne, Victoria, Australia. gosavirr@gmail.com. 3. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 4. Colorectal Surgery Department, Alfred Health, Melbourne, Victoria, Australia. 5. Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 6. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 7. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Abstract
BACKGROUND: There is increasing evidence to support the use of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). However, its safety, efficacy and side effect profile is yet to be completely elucidated. This review aims to assess NAC regimens, duration, compare completion rates, intra-operative and post-operative complication profiles and oncological outcomes, in order to provide guidance for clinical practice and further research. METHODS: PubMed, EMBASE and MEDLINE were searched for a systematic review of the literature from 2000 to 2020. Eight eligible studies were included, with a total of 1213 patients, 752 (62%) of whom received NAC. Of the eight studies analysed, two were randomised controlled trials comparing neoadjuvant chemotherapy followed by oncological resection to upfront surgery and adjuvant chemotherapy, three were prospective single-arm phase II trials analysing neoadjuvant chemotherapy followed by surgery only, one was a retrospective study comparing neoadjuvant chemotherapy followed by surgery versus surgery first followed by adjuvant chemotherapy and the remaining two were single-arm retrospective studies of neoadjuvant chemotherapy followed by surgery. RESULTS: All cases of LACC were determined and staged by computed tomography; majority of the studies defined LACC as T3 with extramural depth of 5 mm or more, T4 and/or nodal positivity. NAC administered was either folinic acid, fluorouracil and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (XELOX) with the exception of one study which utilised 5-fluorouracil and mitomycin. Most studies had NAC completion rates of above 83% with two notable exceptions being Zhou et al. and The Colorectal Cancer Chemotherapy Study Group of Japan who both recorded a completion rate of 52%. Time to surgery from completion of NAC ranged on average from 16 to 31 days. The anastomotic leak rate in the NAC group ranged from 0 to 4.5%, with no cases of postoperative mortality. The R0 resection rate in the NAC group was 96.1%. Meta-analysis of both RCTs included in this study showed that neoadjuvant chemotherapy increased the likelihood of a negative resection margin T3/4 advanced colon cancer (pooled relative risk of 0.47 with a 95% confidence interval) with no increase in adverse consequence of anastomotic leak, wound infection or return to theatre. CONCLUSIONS: Our systematic review and meta-analysis show that NAC is safe with an acceptable side effect profile in the management of LACC. The current data supports an oncological benefit for tumour downstaging and increased in R0 resection rate.
BACKGROUND: There is increasing evidence to support the use of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). However, its safety, efficacy and side effect profile is yet to be completely elucidated. This review aims to assess NAC regimens, duration, compare completion rates, intra-operative and post-operative complication profiles and oncological outcomes, in order to provide guidance for clinical practice and further research. METHODS: PubMed, EMBASE and MEDLINE were searched for a systematic review of the literature from 2000 to 2020. Eight eligible studies were included, with a total of 1213 patients, 752 (62%) of whom received NAC. Of the eight studies analysed, two were randomised controlled trials comparing neoadjuvant chemotherapy followed by oncological resection to upfront surgery and adjuvant chemotherapy, three were prospective single-arm phase II trials analysing neoadjuvant chemotherapy followed by surgery only, one was a retrospective study comparing neoadjuvant chemotherapy followed by surgery versus surgery first followed by adjuvant chemotherapy and the remaining two were single-arm retrospective studies of neoadjuvant chemotherapy followed by surgery. RESULTS: All cases of LACC were determined and staged by computed tomography; majority of the studies defined LACC as T3 with extramural depth of 5 mm or more, T4 and/or nodal positivity. NAC administered was either folinic acid, fluorouracil and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (XELOX) with the exception of one study which utilised 5-fluorouracil and mitomycin. Most studies had NAC completion rates of above 83% with two notable exceptions being Zhou et al. and The Colorectal Cancer Chemotherapy Study Group of Japan who both recorded a completion rate of 52%. Time to surgery from completion of NAC ranged on average from 16 to 31 days. The anastomotic leak rate in the NAC group ranged from 0 to 4.5%, with no cases of postoperative mortality. The R0 resection rate in the NAC group was 96.1%. Meta-analysis of both RCTs included in this study showed that neoadjuvant chemotherapy increased the likelihood of a negative resection margin T3/4 advanced colon cancer (pooled relative risk of 0.47 with a 95% confidence interval) with no increase in adverse consequence of anastomotic leak, wound infection or return to theatre. CONCLUSIONS: Our systematic review and meta-analysis show that NAC is safe with an acceptable side effect profile in the management of LACC. The current data supports an oncological benefit for tumour downstaging and increased in R0 resection rate.
Authors: René A C Vieira; Ademar Lopes; Paulo A C Almeida; Benedito M Rossi; Wilson T Nakagawa; Fabio O Ferreira; Celso A Melo Journal: Rev Hosp Clin Fac Med Sao Paulo Date: 2005-01-11
Authors: Lai Xue; Ashley Williamson; Sara Gaines; Ciro Andolfi; Terrah Paul-Olson; Anu Neerukonda; Emily Steinhagen; Radhika Smith; Lisa M Cannon; Blasé Polite; Konstantin Umanskiy; Neil Hyman Journal: Curr Probl Surg Date: 2018-02-13 Impact factor: 1.909
Authors: M Karoui; A Rullier; G Piessen; J L Legoux; E Barbier; C De Chaisemartin; C Lecaille; O Bouche; H Ammarguellat; F Brunetti; M Prudhomme; J M Regimbeau; O Glehen; A Lievre; G Portier; J Hartwig; G Goujon; B Romain; C Lepage; J Taieb Journal: Ann Surg Date: 2020-04 Impact factor: 12.969
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Søren R Rafaelsen; Claus Dam; Chris Vagn-Hansen; Jakob Møller; Hans B Rahr; Mikkel Sjöström; Jan Lindebjerg; Torben Frøstrup Hansen; Malene Roland Vils Pedersen Journal: Curr Oncol Date: 2022-02-13 Impact factor: 3.109